MEDBOT-B(02252): Tianmai endoscopic surgery Siasun Robot&Automation global commercial orders exceed 200 units

MEDBOT-B (02252) announcement: As of the date of this announcement, the global commercial orders for the group's core product Tumai endoscope surgery Siasun Robot & Automation have exceeded 200 units, covering nearly 50 countries and regions, with nearly 130 units already installed commercially. This milestone in the scale of Tumai's commercial orders and installations signifies the continued and widespread recognition of its clinical value on a global scale, certifying its safety, stability, and reliability. Surgeons from different countries, medical systems, and specialties are incorporating Tumai into their daily surgical practices and long-term discipline development with real and cautious clinical decision-making. Among the nearly 50 countries and regions covered, there are 12 with orders exceeding 5 units, with strong growth in emerging markets such as India, Brazil, and Argentina, where India has accumulated orders of 14 units and Brazil has more than 10 units; developed country markets continue to break through, with countries like Spain and Australia becoming rapid growth points. Tumai's commercialization has formed a new pattern of multi-regional synergistic resonance worldwide, spanning developing countries' emerging markets as well as developed countries' mature healthcare systems. While the globalization layout continues to accelerate, Tumai has made breakthrough progress in depth in single-center clinical applications. According to internal data, dozens of medical institutions in various countries that have completed commercial installations of Tumai have performed over a hundred single-center surgeries, covering a wide range of departments such as urology, general surgery, thoracic surgery, gynecology, pediatric surgery, head and neck surgery, etc. As the world's first remotely operated Siasun Robot & Automation system to be commercially approved, Tumai's remote surgery Siasun Robot & Automation has obtained market approval in nearly 10 countries including China, India, and Brazil. Its applications have covered regions where nearly half of the global population resides and have already entered the normalization and scaled clinical application stage. As of now, Tumai has completed nearly 800 remote surgeries, covering over 20 countries, with a success rate continuing to maintain 100%.